Insider Transactions in Q1 2021 at Kal Vista Pharmaceuticals, Inc. (KALV)
Insider Transaction List (Q1 2021)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 23
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-1.41%
|
$330,000
$33.49 P/Share
|
|
Feb 23
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
31,000
-9.98%
|
$1,023,000
$33.4 P/Share
|
|
Feb 23
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
29,642
-8.49%
|
$978,186
$33.49 P/Share
|
|
Feb 23
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
29,642
+23.85%
|
$177,852
$6.74 P/Share
|
|
Feb 23
2021
|
Christopher Yea CHIEF DEVELOPMENT OFFICER |
SELL
Open market or private sale
|
Direct |
15,000
-6.35%
|
$495,000
$33.49 P/Share
|
|
Feb 07
2021
|
Edward P. Feener CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+12.79%
|
-
|
|
Feb 07
2021
|
Benjamin L Palleiko CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+33.33%
|
-
|
|
Jan 04
2021
|
Thomas Andrew Crockett CEO |
SELL
Open market or private sale
|
Direct |
10,000
-2.57%
|
$180,000
$18.49 P/Share
|